The renin–angiotensin–aldosterone system (RAAS) inhibitors (angiotensin-II receptor blockers [ARB] and angiotensin-converting enzyme [ACE] inhibitors) are the first-line blood pressure-lowering agents administrated for DN treatment [20–23]. This evidence concerns the gene ACE and liver dysplastic nodule.